.png){kind=icon}
.png){kind=icon}
Return
Timing of Preoperative Anti-VEGF for Vitrectomy in Proliferative Diabetic Retinopathy: A Competing-Risks Analysis of a Large Cohort
.png){kind=icon}
PRE
AI
DOI：10.1016/j.oret.2025.12.019.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
To evaluate whether timing of preoperative anti-vascular endothelial growth factor (anti-VEGF) therapy given prior to vitrectomy for proliferative diabetic retinopathy (PDR) influences risks of postoperative vitreous hemorrhage (VH) and traction retinal detachment (TRD).
Journal
IF:
5.7
Papers:
584
Citations:
4.1K